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Abstract
Type 1A diabetes mellitus is caused by speciﬁc and progressive autoimmune destruction of the beta cells in the islets of
Langerhans whereas the other cell types in the islet (alpha, delta, and PP) are spared. The autoantigens of Type 1A diabetes
may be divided into subgroups based on their tissue distributions: Beta-cell-speciﬁc antigens like insulin, insulin derivatives,
and IGRP (Islet-speciﬁc Glucose-6-phosphatase catalytic subunit Related Peptide); neurendocrine antigens such as
carboxypeptidase H, insulinoma-associated antigen (IA-2), glutamic acid decarboxylase (GAD65), and carboxypeptidase E;
and those expressed ubiquitously like heat shock protein 60 (a putative autoantigen for type 1 diabetes). This review will focus
speciﬁcally on insulin as a primary autoantigen, an essential target for disease, in type 1A diabetes mellitus. In particular,
immunization with insulin peptide B:9-23 can be used to induce insulin autoantibodies and diabetes in animal models or used
to prevent diabetes. Genetic manipulation of the insulin 1 and 2 genes reciprocally alters development of diabetes in the NOD
mouse, and insulin gene polymorphisms are important determinants of childhood diabetes. We are pursuing the hypothesis
that insulin is a primary autoantigen for type 1 diabetes, and thus the pathogenesis of the disease relates to speciﬁc recognition
of one or more peptides.
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Introduction
Type 1 diabetes mellitus (T1DM) is characterized by
islet beta cell destruction and the loss of insulin
secretion. The etiology of type 1A diabetes mellitus is
autoimmune, and autoantibodies may be detected
years before overt disease is diagnosed (Juhl and
Hutton). By contrast, type 1B diabetes mellitus is
deﬁned as diabetes resulting from the loss of insulin
secretion but is not immune-mediated. Type 1A
diabetes is a complex disorder involving genetic and
environmental interactions. Type 1A diabetes fulﬁlls
the classical criteria for autoimmune disease (Milgrom
and Witebsky 1962). Humoral autoimmunity deve-
lops over a period of months to years (Yu et al. 1996)
following a mostly hypothetical precipitating environ-
mental insult (Sairenji et al. 1991, Graves et al. 2003,
Norris et al. 2003, Stene et al. 2004) in genetically
susceptible individuals. The proposed model for
diabetes development in Figure 1 suggests that an
individual may experience several years of undetected
beta cell loss before a functional deﬁciency of insulin
secretion results in hyperglycemia. Recently, the
BABYDIAB project published ﬁndings that autoanti-
bodies can be detected as early as nine months of age
in offspring of diabetic parents (Hummel et al. 2004).
Speciﬁc autoantigens such as insulin, proinsulin,
insulin peptide B:9-23, GAD65, IA-2, islet ganglio-
sides (GM2-1), phogrin (IA-2 beta), IGRP, and IA-2
have been identiﬁed (Yu and Eisenbarth, Wegmann
et al. 1994, Dotta et al. 1996, Wong et al. 1999,
Hutton and Eisenbarth 2003). Insulitis preceding
disease has been demonstrated repeatedly in multiple
animal models (Yu and Eisenbarth). Multiple experi-
ments have shown the diabetogenicity of splenic CD4
and CD8 T cells transferred to animals with and
without an autoimmune background or to scid mice
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Unlike other human autoimmune diseases like
Graves Disease or myasthenia gravis, autoantibodies
are not by themselves pathogenic (Marner et al.
1985, Martin et al. 2001). Rather they serve as a
surrogate marker of beta cell damage and insulitis
(Eskola et al. 2003), although studies in the NOD
mouse indicate that transplacental antibodies greatly
enhance progression to diabetes (Greeley et al.
2002).
The number of different biochemical autoanti-
bodies (GAD65, IA-2, insulin) is a strong predictor
of future disease development (Verge et al. 1998,
Hummel et al. 2004). Those individuals expressing 2
or more autoantibodies have a 39% risk of
developing diabetes within 3 years and a 68% risk
of disease within 5 years. In a small study, all ﬁrst-
degree relatives expressing all three autoantibodies
developed diabetes within 5 years (Verge et al. 1996).
Detected via staining of patient serum and frozen
human pancreas, cytoplasmic islet cell antibodies
(ICA) in unaffected ﬁrst-degree relatives of diabetics
confer a 30–50% risk of developing clinical diabetes
within 5–10 years (Eskola et al. 2003). The earlier
the autoantibodies appear in children of type 1
diabetic parents, the more likely and quickly a child
is to progress to multiple autoantibody positivity and
diabetes. The different autoantibody types generally
appear sequentially rather than simultaneously
(Yu et al. 1996) with insulin generally appearing
ﬁrst in young persons developing Type 1A diabetes.
Approximately 10–15% of all adults with diabetes
may have LADA (latent autoimmune diabetes of
adults) as evidenced by the presence of GAD
autoantibodies (Zimmet et al. 1999).
Effector cells in type 1A diabetes
In order to develop a T-cell mediated autoimmune
disease such as type 1 diabetes, at least three
essential immune cell types are necessary. Antigen
presenting cells (APCs) must be capable of present-
ing self-antigens via MHC (major histocompatibility
complex) molecules. There must be T cells that
recognize self-peptides. Lastly in diseases where
autoantibodies are present, there must be B cells that
produce autoantibodies usually to intact self-pro-
teins.
Antigen presentation
APCs only present peptides bound to MHC
molecules. Approximately 40–50% of the genetic
risk for diabetes is attributed to alleles of the MHC
genes (Wucherpfennig 2003). The peptide-binding
groove of an MHC molecule directly inﬂuences
which peptides can be presented by a speciﬁc MHC
allele. As the crystal structure of DQ8 and insulin
peptide shows, some high-risk Class II MHC alleles
(DR3/4 and DQ2/8 in humans and IA
g7 in mice)
bind and present insulin peptides with interesting
and distinct properties. NOD and some high-risk
human alleles do not have a negatively charged
amino acid in position 57 of the MHC beta chain
unlike other MHC types that have an aspartic acid in
this position (Wucherpfennig 2003). This creates a
net positive charge in the P9 binding pocket of the
peptide-binding groove that accommodates peptides
from the B chain of insulin. Class I MHC of the
NOD mice (K
d) can bind residues 15-23 of the B
chain of insulin (B:15-23) and I-A
g7 (class II) can
bind B:9-23. In fact, the P1 and P9 pockets of I-A
g7
bind to anchor residues Glu13 and Glu21 in insulin
whereas other MHC molecules favor hydrophobic
side chains in these positions. Previous experiments
that concluded that I-A
g7 bound peptides poorly
were based on I-A
g7 dissociating from its cognate
peptides in the presence of SDS (Wucherpfennig
2003), an experimental system that may not be
physiologically relevant. Other MHC haplotypes
(DR2/DQ6) confer dominant protection against
diabetes (Redondo et al. 2000). For instance,
substituting proline for histidine at position 56 of I-
A
g7 confers protection against diabetes (Wucherp-
fennig 2003). These data underscore the importance
of MHC in antigen presentation in the development
of type 1A diabetes.
Figure 1. Chronic model for development of type 1 diabetes. A
genetically susceptible individual experiences a triggering event
resulting in insulitis. Due to antigen shedding or inﬂammation,
insulitis may be followed by development of autoantibodies. Some
individuals (likely those with single antibody positivity) do not
progress to diabetes (Hummel et al. 2004) (dotted line) whereas
others experience a slow loss of beta cell mass and insulin secretion,
leading to the development of overt disease. FPIR (ﬁrst phase
insulin response) is a measure of residual beta cell function.
Figure adapted from Teaching Slides (Yu and Eisenbarth) and
Eisenbarth et al.(1988). Thekinetics ofthe development ofdiabetes
may be different in different populations (von Herrath and Bach
2002).
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Thymic selection of the T cell repertoire is key in
many autoimmune diseases. Deletion or inactivation
of self-reactive T cells depends on whether developing
T cells “see” an autoantigen. Evidence for central
tolerance failures in the development of diabetes is
derived from various animal models and human
autoimmune syndromes.
The polyendocrine disorder autoimmune-poly-
endocrinopathy-candidiasis-ectodermal dystrophy
(APECED) or autoimmune polyendocrine syndrome
type I (APS-I) are caused by mutations in the AIRE
gene. The AIRE gene is expressed predominantly in
the medullary epithelial cells of the thymus (with
minor expression in peripheral lymphoid organs but
none in parenchymal tissues) and inﬂuences ectopic
expression of peripheral antigens (Anderson et al.
2002). Patients with APECED often have type 1
diabetes and produce insulin autoantibodies
(Redondo et al. 2000). Mice lacking the aire
protein do not express proinsulin in the thymus,
show an increased number of activated memory
T cells, and display an autoimmune proﬁle
similar to mice subjected to neonatal thymectomy
(Anderson et al. 2002).
The thymus deletes autoreactive T cells in a dose-
dependent manner (Anjos and Polychronakos 2004).
Therefore, expression levels of proteins in the thymus
can also inﬂuence whether a T cell is clonally deleted
or allowed to mature. A variable number of tandem
repeats (VNTR) of a 14-15 base pair sequence found
upstream of the human insulin gene (INS) affects
proinsulin messenger RNA levels in the thymus. Short
alleles are associated with developing type 1 diabetes,
and long alleles are associated with a lower risk of
type1 diabetes (Matejkova-Behanova et al. 2004, Tait
et al. 2004). Thymic expression of proinsulin is
directly related to gene copy number (Chentouﬁ and
Polychronakos 2002). The INS VNTR polymorphism
also affects the levels of GAD65 autoantibodies in
adults with new-onset diabetes and the polymorphism
has a high positive predictive value for future insulin
dependency (Zimmet et al. 1999). This VNTR is
speciﬁc for autoimmune diabetes susceptibility only; it
is not a marker for other autoimmune diseases like
multiple sclerosis or Graves Disease (Tait et al. 2004).
As in the periphery, MHC molecules play a role in
antigen presentation in the thymus. Diabetes in the
NOD mouse has been prevented by expressing
proinsulin 2 in MHC Class II cells (APCs) in the
thymus and spleen (French et al. 1997).
Antibody production
The third immune cell required for type 1 diabetes in
the NOD mouse is the B-lymphocyte. As stated above,
the autoantibodies in human disease are considered to
be markers of disease rather than primarily patho-
genic. In the NOD mouse strains, antibodies are
associated with insulitis, but the insulitis may or may
not progress to diabetes (Robles et al. 2002). Greeley
found that elimination of maternal autoantibodies
prevented disease in genetically susceptible offspring
(Greeley et al. 2002). Since B-lymphocytes serve
multiple functions (antibody producers or antigen
presenters), B-lymphocytes might be pathogenic in
their role as APCs. In the NOD mouse, B-
lymphocytes that present beta-cell antigens are critical
for in vivo priming of islet antigens (Serreze et al.
1998, Noorchashm et al. 2003).
Preproinsulin, proinsulin, and insulin
The initial mRNA transcript for insulin is for
preproinsulin. After the signal sequence that directs
the message to the endoplasmic reticulum is cleaved,
proinsulin is packaged into secretory granules for
export from the pancreas. Inside the secretory
granule, proinsulin is cleaved to insulin and C-
peptide, and the two molecules are present in a 1:1
ratio (Hutton et al.). Proinsulin is an early autoantigen
in the development of diabetes in both mice and man
(Ott et al. 2004).
Mice have two insulin genes (Ins1 and Ins2) on
chromosomes 19 and 7, respectively, whereas humans
possess only one insulin gene (INS) on chromosome
11 that is homologous to Ins2. The two proteins are
very similar in structure; the mRNAs vary only by two
amino acids in the B chain and several in the C peptide
and leader sequences of preproinsulin (Thebault-
Baumont et al. 2003, Moriyama et al. 2003). The Ins2
gene is expressed at much higher levels in the thymus
compared to insulin 1 which is essentially absent from
the thymus (Moriyama et al. 2003). Overall thymic
expression of proinsulin is forty times lower than
pancreatic insulin expression level (Chen et al. 2001).
In young NOD mice, proinsulin message is expressed
in the thymus at similar levels to non-autoimmune
mice (Balb/c and B6), but only splenic T cells from
young NOD mice can be stimulated by proinsulin
peptide B24-C33 (Chen et al. 2001). This particular
epitope is not found in insulin since the C-peptide is
spliced from proinsulin. In older mice (6–8 weeks),
the proliferative response to GAD65 equals that of
proinsulin. GAD65 shares a 13 amino acid sequence
homology with proinsulin BC peptide (Chen et al.
2001). Cross-reactivity between GAD65 and pro-
insulin peptides may be unlikely since a peptide library
screen of GAD65 and proinsulin against T cells
isolated from patients with type 1 diabetes and
individuals with two or more autoantibodies failed to
y i e l da ni m m u n o d o m i n a n te p i t o p eo fG A D 6 5
consistent with cross-reactive priming between
GAD65 and proinsulin (Ott et al. 2004).
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diabetes, insulitis, and insulin autoantibodies at an
accelerated rate compared to Ins2 þ /þ mice and
demonstrate an increased ability to transfer disease to
naı ¨ve animals (Thebault-Baumont et al. 2003,
Moriyama et al. 2003). Heterozygous knockout mice
(Ins2 þ /2) show accelerated disease over normal
wild type NOD mice but less than homozygous
knockout mice (Thebault-Baumont et al. 2003,
Moriyama et al. 2003, Anjos and Polychronakos,
2004). In contrast, Ins1 knockout mice (Ins1 2/2)
are protected from diabetes but not from sialitis or
development of insulin autoantibodies (Moriyama
et al. 2003). Ins1 may be a preferred target for
peripheral anti-insulin autoimmunity whereas the
presence or absence of thymic Ins2 may determine
whether autoimmunity develops or not (Moriyama
et al. 2003). Both native murine insulin sequences can
be recognized by the immune system depending on
speciﬁc histocompatibility alleles.
What are the epitopes?
Many putative epitopes of insulin and proinsulin have
been identiﬁed in humans and mice using a variety of
techniques. Peptides have been eluted from HLA
molecules and sequenced via mass spectroscopy
(Lieberman et al. 2003). Screening peptide libraries
have been used to measure IFN gamma response of
peripheral blood mononuclear cells (PBMCs) isolated
from patients with diabetes (Ott et al. 2004). T cell
clones have been isolated by using whole islets as
antigens (Wegmann et al. 1994). Invitro stimulation of
splenocytes with speciﬁc peptides have been used in
proliferation assays (Chen et al. 2001) and mice have
been challenged/immunized in vivo with speciﬁc
peptides (Moriyama et al. 2003) or received trans-
plants of islets expressing particular antigens (Faideau
et al. 2004). T cell receptor transgenic mice models
have been created (Gregersen et al. 2004).
It is still undetermined which epitope may be ﬁrst or
if there is a single consistent initiating epitope among
all cases of diabetes. It is possible that the multiplicity
of antigenic determinants from a single protein is the
result of epitope spreading, i.e. a single epitope is the
target of the precipitating event within the inﬂamma-
tory milieu of the pancreas, not easily identiﬁed by
examining peripheral blood lymphocytes (Ott et al.
2004), with epitope spreading occurring later in a
second wave of autoimmunity. We hypothesize that
the initial islet peptide recognized will be similar for
individuals with the same MHC alleles, but the
priming event will be one of a host of possible
triggering events. Of note, immunization of NOD
mice with the B:9-23 sequence from insulin 2 prevents
diabetes whereas the B:9-23 peptide from insulin 1
does not (Devendra et al. 2004). The insulin 1 B:9-23
peptide differs from the insulin 2 peptide by a single
amino acid (proline versus serine at position B9).
When NOD mice expressing the B7.1 costimulatory
molecule on islets are immunized with the insulin 1
peptide, diabetes is rapidly induced and when
immunized with the insulin 2 peptide, these mice
have a slower disease onset (Devendra et al. 2004). As
might be expected, the response to the B:9:23 peptide
is MHC-restricted (I-A
g7 and I-A
d respond but I-A
b
does not).
Figure 2 shows several putative epitopes from
preproinsulin in mouse models. Various experiments
have identiﬁed the following CD4 epitopes in mice:
B:2-16 (Halbout et al. 2002), A:7-21 (Daniel and
Wegmann 1996), A:1-15 (Halbout et al. 2002), and
B:9-23 (Abiru et al. 2000). CD8 T cells as well as
CD4 T cells are required for development of T1DM
(Lieberman et al. 2003), and CD8 T cells may be
particularly important for the initiation of disease
(Stene et al. 2004). CD8 T cell clones that bind B:15-
22 and B:15-23 have been isolated and can transfer
disease in mouse models (Wong et al. 1999). Most
recently, NOD mice with both insulin genes knocked
out and replaced with a single amino acid-substituted
insulin 2 gene failed to develop autoimmune diabetes
(Nakayama 2005).
In man, an HLA-DR-restricted T cell clone from a
new-onset patient was found to react with B:11-27
(Schloot et al. 1998). This peptide includes the B:9-
23 peptide that is so important in the MHC-
restricted mouse model. The B:9-23 peptide was also
found to stimulate T cell proliferation in recent-onset
diabetic patients but not in age- or HLA-matched
controls (Alleva et al. 2001). Single T cells cloned
from pancreatic draining lymph nodes isolated from
DR4 type 1 diabetic patients recognize the A: 1-15
insulin peptide (Kent 2005). Using enzyme-linked
immunosorbent spot assays (ELISPOT), Peakman
Figure 2. Linear structure of proinsulin message. The various
putative murine epitopes of preproinsulin are shown as bars below
the structure. The dashed line shows the epitope from a T cell clone
that reactswith insulin but prevents diabetes. See text for references.
*B:9-23 from both proinsulin1 and proinsulin2 prevent or provoke
diabetes in the mouse.
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speciﬁc peptides to which diabetics and controls
respond differentially. Diabetic patients respond with
a pro-inﬂammatory phenotype whereas controls
respond with a regulatory phenotype (Arif et al.
2004). Insulin, proinsulin, and several insulin
peptides were found to stimulate B and T cells in
type 1 diabetic patients and antibody-positive
patients, both with DRB1*04 and DQB1*0302
haplotypes, further emphasizing the need to consider
antigen- and MHC-speciﬁcity together (Durinovic-
Bello et al. 2003).
Prevention of disease by insulin
Using insulin as a prophylactic treatment was tried
because exogenous insulin might allow the pancreas
to “rest,” be able to induce peripheral tolerance, or
ameliorate pancreatic toxicity of excess glucose
(Herold 2004). Subcutaneous, intranasal, and intra-
venous insulin can either delay the onset or reduce
the incidence of diabetes in animal models (Got-
fredsen et al. 1985, Daniel and Wegmann 1996,
Zekzer et al. 1997). Administration of the insulin
peptide B:9-23 has been both provocative as well as
preventive in mouse models (Moriyama et al. 2002,
Liu et al. 2003, Stene et al. 2004) depending on the
genetic background. Since the peptide does not have
the physiological activity of insulin, tolerance
induction might be the mechanism of disease
prevention with B:9-23. In humans, the diabetes
prevention trial (DPT-1) failed to ﬁnd any effect of
parenteral insulin, and the oral trial results have just
been published with a subset showing potential
efﬁcacy (Skyler et al. 2005). Intranasal or inhaled
trials of insulin are on-going. Pilot studies show
better results in patients with normal FPIR (Daaboul
and Schatz 2003).
Conclusion
Type 1A diabetes is a complex disorder involving
multiple genes and environmental inﬂuences. In
human and animal disease, autoantibodies precede
overt disease and maybeused to identify individuals at
risk of developing diabetes. The time between
antibody appearance and onset of disease provides a
therapeutic window of opportunity for preventing
disease. The complexity of the disorder makes it likely
that there are many alternative pathways that lead to
autoimmune diabetes, but loss of central or peripheral
tolerance to insulin is likely a key event in the
pathogenesis of type 1A diabetes.
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